Europe’s CHMP Clears Just Two Drugs: Brintellix And Opsumit
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive opinions for new medicines were relatively scarce in Europe this month, with only Lundbeck's new antidepressant, Brintellix and Actelion's PAH therapy, Opsumit, being recommended for approval.